Amidst slashing of the price targets, CVS has unanimous Buy rating.In a note forwarded to investors on Monday, Vetr’s investment analysts have brought down their current rating of CVS Health to “Hold” from a previous “Buy.” Currently, the firm has set the price target of $105.38 on the stock of the biotech giant. According to firm’s price objective, the company’s current price has the potential of going up by 3.74%.
Two of the prominent corporate personnel have also sold few of the shares they held in the business. According to a legal filing with the SEC, it was revealed that on Wednesday, March 9, the biotech titan’s CEO Larry J. Merlo traded 38,247 shares of the stock. The average price of the shares was $100 and the total transaction was accumulated to be $3,824,700. After the transaction, the CEO owns 261,287 shares which worth around $26,128,700.
Jonathan C. Roberts, company’s EVP, had also earlier traded around 23,355 shares. The average price of the shares was $92,89 and the total transaction worth around $2,128,700. The transaction left the executive vice president with the ownership of around 75,315 shares out of the company’s stocks worth $6,993,750.
CVS reported the latest quarterly earnings on Tuesday, February 9. It disclosed an EPS of $1.53 and earned the revenue of $41.15 billion modestly crossing the analysts’ expectations of $41.12 billion. On a year-over-year basis, its revenue went up by 11%. For the current year, however, analysts expect the company to post EPS of $5.82.
CVS has also announced the quarterly dividend which it is more likely to pay on May 2, Monday. Additionally, on Friday, April 22, it will issue a $0.425 per share dividend for the investors of record.
Many other analysts have also forwarded their comments on CVS. Barclays, for instance, increased the price target of the stock to hefty $115 from $110 in addition to giving the “overweight” rating to the stock. Mizuho, however, slashed down the price target to $104 from $113 while simultaneously rating the stock “Buy.”
Leerink Swann set a price target of $110 of the stock and reiterated “Buy” rating. Oppenheimer analysts took the stock price objective to $117 from $115. The firm gave “Outperform” rating to the stock. Finally, in a research note expanded on Tuesday, March 15, Credit Suisse forwarded its expectations relating to the stock and rated the stock at “Outperform” while setting the price target at $115.
One analyst has issued a strong buy rating for the stock, nineteen analysts have rated the stock as “Buy,” and five analysts have given “Hold” rating to the stock. Overall, CVS Health Corp. has a consensus “Buy” rating while its average price target is set on $113.10.
Two of the prominent corporate personnel have also sold few of the shares they held in the business. According to a legal filing with the SEC, it was revealed that on Wednesday, March 9, the biotech titan’s CEO Larry J. Merlo traded 38,247 shares of the stock. The average price of the shares was $100 and the total transaction was accumulated to be $3,824,700. After the transaction, the CEO owns 261,287 shares which worth around $26,128,700.
Jonathan C. Roberts, company’s EVP, had also earlier traded around 23,355 shares. The average price of the shares was $92,89 and the total transaction worth around $2,128,700. The transaction left the executive vice president with the ownership of around 75,315 shares out of the company’s stocks worth $6,993,750.
CVS reported the latest quarterly earnings on Tuesday, February 9. It disclosed an EPS of $1.53 and earned the revenue of $41.15 billion modestly crossing the analysts’ expectations of $41.12 billion. On a year-over-year basis, its revenue went up by 11%. For the current year, however, analysts expect the company to post EPS of $5.82.
CVS has also announced the quarterly dividend which it is more likely to pay on May 2, Monday. Additionally, on Friday, April 22, it will issue a $0.425 per share dividend for the investors of record.
Many other analysts have also forwarded their comments on CVS. Barclays, for instance, increased the price target of the stock to hefty $115 from $110 in addition to giving the “overweight” rating to the stock. Mizuho, however, slashed down the price target to $104 from $113 while simultaneously rating the stock “Buy.”
Leerink Swann set a price target of $110 of the stock and reiterated “Buy” rating. Oppenheimer analysts took the stock price objective to $117 from $115. The firm gave “Outperform” rating to the stock. Finally, in a research note expanded on Tuesday, March 15, Credit Suisse forwarded its expectations relating to the stock and rated the stock at “Outperform” while setting the price target at $115.
One analyst has issued a strong buy rating for the stock, nineteen analysts have rated the stock as “Buy,” and five analysts have given “Hold” rating to the stock. Overall, CVS Health Corp. has a consensus “Buy” rating while its average price target is set on $113.10.